SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2011 / Cilt: 59 - Sayı: 2

Fondaparinux treatment in heparin induced thrombocytopenia: a case report

Heparine bağlı trombositopeninin tedavisinde fondaparinuks: Bir olgu sunumu

Ahmet KORKMAZ
Funda ÖZTUNA
Tevfik ÖZLÜ
Yılmaz BÜLBÜL
Savaş ÖZSU
Pages
178–183
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We tried to make an overview of new treatment choices along with current literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Heparin induced thrombocytopenia is a serious complication of heparin therapy that has a high levels of morbidity and mortality due to thrombotic complications.
📊
Key Findings & Data:Heparin induced thrombocytopenia usually develops between days 5 and 14 (inclusive) following initiation of heparin.
💡
Conclusion & Impact:We tried to make an overview of new treatment choices along with current literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Heparin induced thrombocytopenia is a serious complication of heparin therapy that has a high levels of morbidity and mortality due to thrombotic complications. Heparin induced thrombocytopenia usually develops between days 5 and 14 (inclusive) following initiation of heparin. When heparin induced thrombocytopenia is suspected, heparin should be discontinued and treatment with a direct thrombin inhibitor should be initiated. Heparin induced thrombocytopenia occurs more frequently with unfractionated heparin than with low molecular weight heparin. In this manuscript, we presented a case diagnosis with heparin induced thrombocytopenia who was given low molecular weight heparin for prophylaxis. We tried to make an overview of new treatment choices along with current literature.

Özet

Heparine bağlı trombositopeni heparin tedavisinin nadir, ancak ciddi bir komplikasyonudur ve trombotik komplikasyonlar nedeniyle yüksek morbidite ve mortaliteye sahiptir. Heparine bağlı trombositopeni heparin kullanımını takiben genellikle 5-14. günlerde gelişir. Heparine bağlı trombositopeni geliştiğinde heparin tedavisi kesilmeli ve direkt trombin inhibitörleri başlanmalıdır. Heparine bağlı trombositopeni standart heparin kullanımında düşük molekül ağırlıklı heparine göre daha sık gözlenmektedir. Bu yazıda düşük molekül ağırlıklı heparin profilaksisi sonrası, heparine bağlı trombositopeni gelişen bir olgu güncel literatür eşliğinde sunulmuştur.

🔖

Cite This Article

KORKMAZ, A., ÖZTUNA, F., ÖZLÜ, T., BÜLBÜL, Y., ÖZSU, S. (2022). Fondaparinux treatment in heparin induced thrombocytopenia: a case report. Tüberküloz ve Toraks, Cilt: 59 - Sayı: 2, 178–183. https://ajindex.com/articles/618786

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008; 112: 2606-15
  2. Kelton JG. Heparin-induced thrombocytopenia: an overview. Blood Rev 2002; 16: 77-80
  3. Baglin TP. Heparin-induced thrombocytopenia/thrombosis syndrome (HIT): diagnosis and treatment. Platelets 1997; 8: 72-82
  4. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 2007; 131: 1644-9
  5. Levine RL, McCallum D, Hursting MJ. How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia? Chest 2006; 130: 631-2
  6. Warkentin TE, Grienacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 2004; 126: 311-37
  7. Franchini M. Heparin-induced thrombocytopenia: an update. Thrombosis Journal 2005; 3: 14
  8. Warkentin TE, Greinacher A, Koster A, Lincoff MA. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008; 133: 340-80
  9. Demir M, Duran E, Yigitbasi O, Vural O, Kurum T, Yuksel M, et al. Incidence of antiheparin-platelet factor 4 antibodies and heparin- induced thrombocytopenia in Turkish patients undergoing cardiac surgery. Clin Appl Thromb Hemost 2007; 13: 279-84
  10. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108: 2937- 41. Epub 2006 Jul 20
  11. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5
  12. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparininduced thrombocytopenia. Am J Med 1999; 106: 629-35
  13. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-7
  14. Akagün T, Sönmez M, Yılmaz M ve ark. Heparinin indüklediği trombositopenide fondaparinux tedavisi: Olgu sunumu. International Journal of Hematology and Oncology 2006; 16: 141-4
  15. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92: 494-7
  16. Sünmez S, Okumuş G, Kiyan E, Ece T, Arseven O. A case of heparin induced thrombocytopenia treated with lepirudin infusion: case rep